Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Equity Income (2024 - 2025)

Historic Equity Income for BioNexus Gene Lab (BGLC) over the last 2 years, with Q2 2025 value amounting to $23742.0.

  • BioNexus Gene Lab's Equity Income fell 7318.26% to $23742.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$145351.0, marking a year-over-year change of. This contributed to the annual value of $69476.0 for FY2024, which is 7734.09% down from last year.
  • Latest data reveals that BioNexus Gene Lab reported Equity Income of $23742.0 as of Q2 2025, which was down 7318.26% from $4514.0 recorded in Q1 2025.
  • BioNexus Gene Lab's Equity Income's 5-year high stood at $88532.0 during Q2 2024, with a 5-year trough of -$173607.0 in Q4 2024.